AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$TWST

Finn Patrick John sold $9.2M of TWST

Finn Patrick John (President and COO) sold 78,355 shares of Twist Bioscience Corp (TWST) at an average of $117.64 ($115.90–$122.58, $9.22M total) across 7 trades on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Finn Patrick John
Published Aug 20, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishMed
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, which traders may weigh against recent stock performance.

02

Market read

Primary source insider sale; modest materiality for short‑term traders.

03

What to watch

No change in company fundamentals disclosed; the insider retains a sizable stake.

Relevance 5/10Novelty 8/10Timing: filed on 2026-08-20, reflects recent 2026-08-18 transaction

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan sale by a senior officer is a standard reporting requirement.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

President and COO Finn Patrick John sold 78,355 shares for $9.2M via a 10b5-1 plan, reducing his stake to 214,678 shares.

Expected impact

Potential modest downside pressure over the next few days.

Evidence & confidence

A $9.2M sale by a top executive signals possible concerns, but the sale is pre‑arranged under a 10b5‑1 plan, limiting immediate inference.

Market effects

Sector

May raise questions about executive confidence in Twist Bioscience's growth prospects.

Regional

Limited to US biotech sector.

Global

Low, confined to Twist Bioscience investors.

Counterpoint

What could challenge this read

The sale is pre‑arranged; could be routine portfolio rebalancing rather than a negative signal.

Key entities

  • Individual
    Finn Patrick John

    President and COO of Twist Bioscience, reporting officer.

  • Company
    Twist Bioscience Corp

    Biotech company specializing in DNA synthesis.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

SEP 17
$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

timothysykes.com2 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min
SEP 17
$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

stockstotrade.com3 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

timothysykes.com2 min